cp wire

CP Wire Articles

  • At Week 96, 73.1 percent of the treatment group achieved viral suppression
  • Previously reported - at week 48 DOR met its primary efficacy endpoint of non-inferiority compared to DRV+r... read more
Tue, 07/24/18 - 09:55 am
  • States with highest use of Truvada for PrEP had significant declines in HIV diagnoses
  • States with the lowest use saw increases in HIV diagnoses
  • Truvada was approved for HIV... read more
Tue, 07/24/18 - 09:43 am

Speaker Book is an application that provides a network of doctors’ financials payments from pharmaceutical companies. In this tutorial, we will be demonstrating how to understand and navigate the... read more

Mon, 07/23/18 - 04:38 pm
  • Ph II study will include up to 150 patients
  • The study will include testing in head and neck cancer, non-small cell lung cancer and gastric and gastroesophageal junction... read more
Mon, 07/23/18 - 09:57 am
  • Changes in familial amyloid polyneuropathy and polyneuropathy disability were significant
  • Earlier indirect comparison of patisiran vs rival indicated patisiran superiority
  • ... read more
Mon, 07/23/18 - 09:40 am
  • Puretech will be eligible to receive payments over $1 billion
  • The company has 11 products under development with affiliates
  • PureTech is focused on developing therapies based... read more
Fri, 07/20/18 - 09:43 am

Sage Bionetworks on 7/20/18 announced the launch of the Agora platform (agora.ampadportal.org) an interactive, web-based tool that allows researchers to explore curated genomic analyses of... read more

Fri, 07/20/18 - 09:25 am

The FDA is forming a work group to consider situations under which the FDA would allow the importation of drugs that would be suitable substitutes for the FDA-approved version of medically-... read more

Thu, 07/19/18 - 12:18 pm
  • A statistically significant proportion of patients achieved clinical remission at week 52 compared to placebo
  • Vedolizumab is a humanized monoclonal antibody specifically designed to... read more
Thu, 07/19/18 - 10:07 am

Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability... read more

Thu, 07/19/18 - 09:44 am
  • Trajenta demonstrated cardiovascular safety in adults with type 2 diabetes and high vascular risk, with no need for dose adjustments regardless of kidney function
  • The study included... read more
Thu, 07/19/18 - 09:31 am
  • Kisqali approved under Real Time Oncology Review Program
  • One of two new programs intended to make the development of cancer drugs more effecient
  • Approval came less than one... read more
Wed, 07/18/18 - 01:20 pm
  • Observed responses to date show overall tumor reduction ranged from 60% to greater than 90%
  • Company is expanding trial cohort up to 30 additional patients
  • CLR 131 has orphan... read more
Wed, 07/18/18 - 09:58 am
  • TAK-935/OV935 is a first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase
  • TAK-935/OV935 may potentially treat rare epilepsies by inhibiting CH24H to decrease 24HC levels... read more
Wed, 07/18/18 - 09:43 am
  • PDUFA target date is 1/18/19
  • Sacituzumab govitecan is an antibody drug conjugate (ADC)
  • If appproved it would be the first ADC approved for mTNBC
  • Company has another... read more
Wed, 07/18/18 - 09:27 am

SPEAKER BOOK APP is the platform where patients advocates, doctors, and biotech investors can look at conflicts of interest in Pharma to understand what is going on under the surface of... read more

Tue, 07/17/18 - 03:25 pm

FDA commissioner, Scott Gottleib, released a statement on 7/17/18 discussing new draft guidance related... read more

Tue, 07/17/18 - 10:18 am
  • Company received $49 million dollar funding round in November of 2017
  • INZ-701 received Orphan Drug Designation in both US and Europe

Inozyme Pharma (Inozyme) announced... read more

Tue, 07/17/18 - 09:41 am
Tue, 07/17/18 - 09:35 am


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.